BR112017022022A2 - arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas) - Google Patents

arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)

Info

Publication number
BR112017022022A2
BR112017022022A2 BR112017022022A BR112017022022A BR112017022022A2 BR 112017022022 A2 BR112017022022 A2 BR 112017022022A2 BR 112017022022 A BR112017022022 A BR 112017022022A BR 112017022022 A BR112017022022 A BR 112017022022A BR 112017022022 A2 BR112017022022 A2 BR 112017022022A2
Authority
BR
Brazil
Prior art keywords
arenaviruses
tumors
prevention
enhanced
treatment
Prior art date
Application number
BR112017022022A
Other languages
English (en)
Other versions
BR112017022022A8 (pt
Inventor
Kalkavan Halime
Sebastian Lang Karl
Original Assignee
Sebastian Lang Karl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sebastian Lang Karl filed Critical Sebastian Lang Karl
Publication of BR112017022022A2 publication Critical patent/BR112017022022A2/pt
Publication of BR112017022022A8 publication Critical patent/BR112017022022A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção refere-se a arenavírus para uso no tratamento e/ou prevenção de tumores, e também a um método para a preparação de arenavírus com propriedades (aprimoradas) de regressão de tumor.
BR112017022022A 2015-04-17 2016-04-15 Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas) BR112017022022A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015207036.0A DE102015207036A1 (de) 2015-04-17 2015-04-17 Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
PCT/EP2016/058347 WO2016166285A1 (de) 2015-04-17 2016-04-15 Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften

Publications (2)

Publication Number Publication Date
BR112017022022A2 true BR112017022022A2 (pt) 2019-01-22
BR112017022022A8 BR112017022022A8 (pt) 2023-03-07

Family

ID=55759589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022022A BR112017022022A8 (pt) 2015-04-17 2016-04-15 Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)

Country Status (9)

Country Link
US (2) US20180117137A1 (pt)
EP (1) EP3283104A1 (pt)
JP (2) JP7039037B2 (pt)
CN (1) CN108025054B (pt)
BR (1) BR112017022022A8 (pt)
CA (1) CA2982873A1 (pt)
DE (1) DE102015207036A1 (pt)
HK (1) HK1251168A1 (pt)
WO (1) WO2016166285A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075250A1 (en) 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN107921117B (zh) 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
EP3371316B1 (en) 2015-11-04 2022-10-19 Hookipa Biotech GmbH Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
WO2018185307A1 (en) * 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
MX2023009650A (es) 2021-02-26 2023-08-24 Abalos Therapeutics Gmbh Nuevas particulas viricas con fines terapeuticos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
WO2011056993A1 (en) * 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften

Also Published As

Publication number Publication date
HK1251168A1 (zh) 2019-01-25
DE102015207036A1 (de) 2016-10-20
EP3283104A1 (de) 2018-02-21
CN108025054A (zh) 2018-05-11
WO2016166285A1 (de) 2016-10-20
CA2982873A1 (en) 2016-10-20
US11801294B2 (en) 2023-10-31
JP7039037B2 (ja) 2022-03-22
JP7273102B2 (ja) 2023-05-12
JP2018515130A (ja) 2018-06-14
CN108025054B (zh) 2022-12-23
US20180117137A1 (en) 2018-05-03
JP2021129589A (ja) 2021-09-09
US20190151436A1 (en) 2019-05-23
BR112017022022A8 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
PH12018500906A1 (en) Antibodies specifically binding pd-1 and their uses
BR112018073384A2 (pt) polinucleotídeos moduladores
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
EA202091540A1 (ru) Антитела к lilrb2
PH12016501763A1 (en) Multispecific antibodies
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: KARL SEBASTIAN LANG (DE)

B25A Requested transfer of rights approved

Owner name: ABALOS THERAPEUTICS GMBH (DE)